Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $28.44M fell 20.4% year over year, behind the +14.6% change in trailing-twelve-month research & development. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at +8.4% a year.

Context

  • Research & development amounted to 50.6% of revenue in FY2025, up 13.1 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.4% toward the trailing-twelve-month pace of +14.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.44M-2.0% QoQ
Last fiscal yearDec 2025
$109.27M+46.8% YoY
LTMMar 2026
$101.99M+14.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.4%——
1 year+46.8%——
3-year CAGR+8.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
109.27M USD
Year-over-year change
+46.8%
4-year CAGR
+9.7%

Research & Development vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 research & development of $101.99M is the 6th highest of the 11 companies compared; the peer median is $113M.
  • Its year-over-year change of +14.6% is the 4th highest of 11, against a peer median of -7.2%.
  • Research & development amounts to 46.8% of revenue for VNDA, versus a peer median of 1423.3%.
VNDA Competitors Peer median
Research & Development for VNDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B +22061.7%+5.1%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$159.57M +37.4%+18.6%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$143.25M +11.2%+28.8%2496.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M -32.1%-16.3%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$127.75M -3.1%+30.4%350.1%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$101.99M +14.6%+8.4%46.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$98.25M -44.3%-8.8%216.6%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$92.92M +60.8%+57.0%—
HUMAHumacyte, Inc.LTM Mar 2026$73.35M -11.4%+3.1%3638.2%
SGMTSagimet Biosciences Inc.LTM Mar 2026$30.71M -36.7%+16.2%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$19.19M -29.2%-8.6%—
Peer median (excluding VNDA) $113M-7.2%+10.6%1423.3%

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue268.68M254.38M192.64M198.77M216.11M
Cost of Revenue25.63M24.28M14.8M11.31M13.04M
Gross Profit243.05M230.1M177.84M187.46M203.06M
Gross Margin90.5%90.5%92.3%94.3%94.0%
Research & Development75.36M85.77M76.82M74.43M109.27M
Selling, General & Admin124.05M136.49M112.88M146.41M237.95M
Operating Expenses200.89M223.77M191.8M228.12M354.23M
Depreciation & Amortization2.84M2.73M3.01M8.13M11.92M
EBITDA45.21M14.03M9.35M(14.79M)(126.73M)
EBITDA Margin16.8%5.5%4.9%-7.4%-58.6%
Operating Income42.17M6.33M(13.95M)(40.66M)(151.17M)
Operating Margin15.7%2.5%-7.2%-20.5%-70.0%
Interest Income199K0000
Interest Expense00000
Other Income / Expenses199K4.97M20.29M17.74M12.52M
Income Before Tax42.36M11.3M6.34M(22.92M)(138.65M)
Pre-Tax Margin15.8%4.4%3.3%-11.5%-64.2%
Income Tax Expense9.21M5.03M3.83M(4.02M)81.83M
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Net Margin12.3%2.5%1.3%-9.5%-102.0%
EPS (Basic)0.600.110.04(0.32)(3.74)
EPS (Diluted)0.580.110.04(0.32)(3.74)
Weighted Avg Shares55.55M56.46M57.38M58.15M58.93M
Weighted Avg Shares (Diluted)56.92M56.98M57.56M58.15M58.93M

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.